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Dear Editors,  
Bleeding events are the most relevant complications during oral anticoagulant treatment (OAT). They have 
been reported to occur at a rate of about 1.35 cases each 100 patients/year [1]. In very rare instances, OAT-
related bleeding in patients with INR values within the therapeutic range may be associated with a 
mutation of the factor IX (FIX) gene. Two propeptide mutations have been described at locus- 10: Ala 
(GCC)-10 Val (GTC) and Ala (GCC)-10 Thr (ACC) [2,3]. The propeptide sequence at locus-10 plays an 
important role in the anticoagulant effect of vitamin K antagonists (VKA), since it contains the hepatic γ-
carboxylase binding site [4]. In the presence of a propeptide locus-10 mutation, hepatic γ-carboxylase 
binding to the FIX protein is markedly reduced. This reduced binding capacity has no clinical implications 
(except during OAT), since the FIX plasma level is within the normal range. When patients with the 
mutation are on OAT, the lack of biologically active vitamin K associated with reduced binding of γ-
carboxylase to the coagulation profactors, may induce a reversible but serious bleeding. This happens 
anytime, from days to weeks, after starting VKA treatment. The bleeding is caused by a rapid decrease in 
FIX activity (FIX:C), which drops to disproportionately lower values compared with the others vitamin-K 
dependent coagulation factors. FIX:C levels drop so low that laboratory data mimic acquired haemophilia B. 
Thus, patients with the mutation cannot be detected by routine monitoring of the INR. However, the 
sudden and disproportionately severe drop in factor IX plasma levels (b3%) induced by OAT leads to 
persistently abnormal prolongation of activated partial thromboplastin time (aPTT). The morbidity 
associated with VKA–related bleeding, and the possibility of identifying mutated patients by performing 
aPTT has led us to question feasibility of aPTT screening in all patients on VKA. The main argumentation 
against aPTT screening is the low prevalence of the mutation [5–7]. A 61 year old man was admitted to the 
emergency department because of an ”idiopathic” proximal deep-vein thrombosis of the right leg. He was 
treated with LMWH, followed by VKA. Heterozygosity for Factor V Leiden mutation, and no other 
thrombophilic abnormality, was found. After about two months of OAT the patient went to the emergency 
department of another hospital on account of severe pain and widespread ecchymosis of the right hand, 
which occurred the day after using a drill. Spontaneous muscle bleeding of the right thigh was also 
reported. Laboratory data showed an INR value of 2.15, but an abnormally prolonged aPTT ratio 4.93 (n.v. ≤ 
1.2). The patient was discharged with a diagnosis of OAT related bleeding. He had never experienced any 
bleeding complications before starting OAT and there was no history of bleeding in his family. One month 
later, the patient returned to the same emergency department because of bilateral leg pain caused by deep 
muscle bleeding. INR was 2.1 and aPTT ratio was 5.63. The patient was again discharged with the same 
diagnosis. VKA dose was reduced and paracetamol was administered.  
Two days later, the patient came to our hospital because of worsening of the bleeding, widespread 
ecchymosis on the chest, legs, hands and arms, and great difficulty in swallowing. Physical examination 
revealed tongue and pharynx haematoma. Laboratory data results were: haemoglobin 6.9 g/dl, INR 2.21 
and aPTT ratio 5.38. VKA was discontinued and the patient underwent blood transfusion. Three days after 
discontinuing OAT, INR returned to 1.3 and aPTT ratio to 1.85, while after seven days both INR and aPTT 
ratio returned to normal values (Fig. 1). At the same time, factors II, VII and X were assayed and found 
within normal range, while factor IX was about 40%. Haematologic counselling was then requested. The 
patient's clinical history showed that both INR and aPTT ratio were within normal ranges before starting 
OAT. The patient reported no previous significant bleeding episodes, and familial bleeding tendency was 
excluded, while inherited bleeding tendency was unlikely. Due to the normal platelet count and normal 
antithrombin plasma levels, we ruled out disseminated intravascular coagulation. The possible presence of 
antibodies against factor VIII:C o IX:C was ruled out because of the quick and spontaneous return to normal 
aPTT ratio values after OAT discontinuation. The only anomaly we observed in coagulation tests was a 
disproportionate aPTT ratio prolongation when compared to INR prolongation. A literature search was then 
carried out and a mutation of the factor IX propeptide was hypothesized. This is a genetic predisposition to 
bleeding during OAT. Blood samples were sent off for molecular evaluation. The first three exons of the 
factor IX gene were amplified and sequenced. Whole exon 1 was amplified by the following primers: 
forward 5’-ATT GAG GGA GAT GGA CAT TAT T-3’ (nt 2892–2913) and reverse 5’-AGT GAA GAA GAC AGC 
ATC AGA TAT-3’ (nt 3159–3136); exons 2 and 3 were amplified together using forward 5’-TTC ATG ATG TTT 
TCT TTT TTG CTA-3’ (nt 9237–9260) and reverse 5’-TGC AGA GAA AAA ACC CAC AT-3’ (nt 9737–9718) 
primers (Gene Bank K02402.1). PCR amplifications were run for 30 cycles with a starting denaturation at 95 
°C for 5 min, 95 °C for 30 s, 58 °C for 30 s and final extension at 72 °C for 7 min. Direct nucleotide 
sequencing revealed a hemizygous -10Ala (GCC)-NThr (ACC) mutation. Only few case reports concerning 
the bleeding tendency in patients on OAT with factor IX propeptide mutation are present in the literature: 
most cases diagnosed in Switzerland and Germany were due to a founder mutation, with a clear regional 
focus [8–12]. To our knowledge this is the first case reported in Italy and actually it is not known if the 
mutation has an independent origin or results from a common founder. The bleeding tendency is usually 
severe, but the prevalence of the disorder in the general population is very low, although probably 
underdiagnosed. In our case, the patient had a very serious, life-threatening bleeding event. We highlight 
the fact that the significant aPTT prolongation was never considered a severe laboratory anomaly. Factor IX 
propeptide mutation is not well known among general practitioners or in the emergency setting. Due to the 
low prevalence of the defect in the general population, aPTT screening is proven not to be cost effective if 
evaluated in all patients on OAT. Data from literature and our experience suggest that if a male patient 
have significant bleeding events in the first weeks or months of OAT and INR is within the therapeutic 
range, the aPTT should be performed. Immediate OAT withdrawal and replacement with an alternative 
anticoagulant treatment would prevent a worsening of bleeding symptoms. 
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Fig. 1. International Normalized Ratio (INR-continuous line ) and Activated Partial Thromboplastin Time 
Ratio (aPTTR-dotted line) during Oral Anticoagulant Therapy (OAT). Arrows indicate bleeding events and 
OAT reduction or discontinuation. 
 
